Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients

**Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients**
*Nov. 07, 2025 4:16 AM ET*

**Gain Therapeutics, Inc. (GANX) Stock**
**Sector:** Biotechnology | **Strategy:** Investing
**Followers:** 262

—

### Summary

Gain Therapeutics has reported functional improvement in Parkinson’s disease (PD) patients treated with GT-02287 during its Phase 1b trial. The treatment notably improved MDS-UPDRS Part III motor scores, signaling enhanced motor function.

GT-02287 targets the misfolding of GCase proteins early in the disease process, potentially offering superior efficacy compared to competitors in the PD treatment landscape.

Despite this promising data and significant market potential, Gain Therapeutics’ market capitalization remains relatively low at $66 million. Given recent trial results and the trend of higher-valued biotech acquisitions, this valuation appears deeply undervalued.

I am reiterating a **Strong Buy** rating for GANX.

—

### Investment Thesis

I am updating my coverage of Gain Therapeutics (GANX) following the recent announcement of functional improvement in Parkinson’s patients.

About a year ago, I covered Gain Therapeutics when the company had recently completed key Phase 1b trials, but since then, the positive clinical outcomes provide even stronger evidence for GT-02287’s potential.

—

### About the Author

I am a long-term investor primarily focused on growth markets, artificial intelligence, and biotech opportunities in my more volatile portfolio. My strategy targets undervalued and under-the-radar stocks with solid scientific foundations and strong growth potential.

My investment interests span semiconductors, mining, shipping, and dividend-yielding stocks. I have been investing since 2021 as an independent investor, supported by a vast network facilitating insight sharing.

I avoid coverage of cryptocurrencies, traditional banking, ETFs, retirement funds, and real estate, as these are outside my core focus.

My investment style is inspired by Warren Buffett, adapted to riskier, high-growth investments. My portfolio ranges across all cap sizes, with a primary focus on the U.S. market, occasionally including select European or Canadian equities.

I am an avid reader of investing literature, including books, websites, articles, and blogs.

Professionally, I serve as deputy director general in a leading European sector organization and hold a Master’s Degree in Law.

The name “Tejo” reflects the river running through Lisbon, connecting to my roots.

—

### Analyst’s Disclosure

I hold a beneficial long position in the shares of GANX, either through stock ownership, options, or other derivatives. This article expresses my own opinions and I have not received any compensation for writing it other than from Seeking Alpha. I have no business relationships with any companies mentioned in this article.

—

### Important Disclaimer

Past performance does not guarantee future results. This article does not constitute a recommendation or advice as to whether any investment is suitable for a particular investor.

The views expressed are those of the author and may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker, U.S. investment adviser, or investment bank. Analysts on Seeking Alpha may include professional and individual investors who are not licensed or certified by any regulatory body.

—

**Comments**
*[Section for user comments and discussion]*

—

Leave a Reply Cancel reply